Application of Hepatoprotector Remaxol in the Treatment of Patients Co-Infected with Tuberculosis, HIV, and Chronic Hepatitis C

Objective: to study effectiveness of remaxol inclusion in pathogenetic therapy scheme for patients with pulmonary tuberculosis and HIV infection in combination with Chronic hepatitis C against the background of alcohol- and drug-related liver damage. Material and methods: 132 case histories of patients with pulmonary tuberculosis and HIV infection, occurring against the background of liver pathology of various origins, were analyzed. Depending on its type and treatment regimen, the patients were divided into the following groups and subgroups: the main group (received Remaxol in the therapy scheme - 400 ml intravenously 1 time per day for 10 days) and control (without maintenance therapy). The first group included patients with concomitant drug-related liver damage, the second - with chronic hepatitis C, the third - with alcohol-related liver damage, and the fourth - with chronic hepatitis C and chronic alcohol intoxication. All patients were examined over time - before the start of the therapy and within 2 weeks after it began: in addition to general blood test, the level of total bilirubin and alanine aminotransferase was studied. Results: The inclusion of Remaxol in the treatment regimen of patients contributed to more rapid relief of dyspeptic disorders and pain, as well as decrease in cytolysis rates. Conclusion: The use of hepatoprotector Remaxol in complex treatment of patients with pulmonary tuberculosis and HIV infection with concomitant chronic hepatitis C on the background of alcohol- and drug-related liver damage contributes to improvement of the functional state of liver and, as a result, increases the effectiveness of treatment.

tuberculosis, HIV infection, viral hepatitis C, pathogenetic therapy, Remaxol, hepatotropic effect